{"groups":[{"description":"Olaparib (AZD2281) 200 mg oral capsules twice daily","id":"FG000","title":"Olaparib 200 mg bd"},{"description":"Olaparib (AZD2281) 400 mg oral capsules twice daily","id":"FG001","title":"Olaparib 400 mg bd"},{"description":"Liposomal doxorubicin 50 mg/m2 intravenously every 4 weeks","id":"FG002","title":"Liposomal Doxorubicin"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"comment":"Patients randomised","groupId":"FG000","numSubjects":"32"},{"comment":"Patients randomised","groupId":"FG001","numSubjects":"32"},{"comment":"Patients randomised","groupId":"FG002","numSubjects":"33"}],"type":"STARTED"},{"achievements":[{"comment":"Patients who received olaparib treatment","groupId":"FG000","numSubjects":"32"},{"comment":"Patients who received olaparib treatment","groupId":"FG001","numSubjects":"32"},{"comment":"1 of 33 patients did not receive Liposomal Doxorubicin. Patient voluntarily discontinued","groupId":"FG002","numSubjects":"32"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Randomised Part"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"13"}],"type":"Condition under investigation worsened"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"6"}],"type":"Other reason"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"Other"}],"milestones":[{"achievements":[{"comment":"Patients who received treatment","groupId":"FG000","numSubjects":"32"},{"comment":"Patients who received treatment","groupId":"FG001","numSubjects":"32"},{"comment":"Patients who received Liposomal doxorubicin 50 mg/m2","groupId":"FG002","numSubjects":"32"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"25"}],"type":"Discontinued Initial Study Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"comment":"Crossover dosage was 400 mg bd Olaparib","groupId":"FG002","numSubjects":"14"}],"type":"Crossover to Olaparib"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"5"}],"type":"Ongoing Crossover at DCO"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"9"}],"type":"Discontinued Crossover"},{"achievements":[{"comment":"Ongoing initial study treatment at primary data cut-off","groupId":"FG000","numSubjects":"10"},{"comment":"Ongoing initial study treatment at primary data cut-off","groupId":"FG001","numSubjects":"12"},{"comment":"Patients ongoing initial study treatment (Liposomal doxorubicin)","groupId":"FG002","numSubjects":"7"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"25"}],"type":"NOT COMPLETED"}],"title":"Ongoing Initial Study Treatment at DCO"}],"preAssignmentDetails":"97 of 125 screened women with advanced BRCA 1/2 ovarian cancer who had chemotherapy were randomized","recruitmentDetails":"First patient enrolled on 30 July 2008 and last patient on 3 March 2009 at 25 centres in 9 countries"}